Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07281261 · ClinicalTrials.gov registry record · NA
tAN for Substance Use Disorder
A NA study, sponsored by Spark Biomedical.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT07281261 is a NA study that is actively recruiting participants, run by Spark Biomedical. The registered enrollment target is 20 participants.
The verdict
NCT07281261, a NA study, is actively recruiting participants, sponsored by Spark Biomedical.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
The study will involve a 5-day tAN treatment to attenuate alcohol withdrawal syndrome (AWS) and alter resting state functional connectivity (RSFC) between OFC and striatum in patients with alcohol use disorder (AUD). Enrolled participants will wear the tAN device on-site (at The Menninger Clinic) for the 5-day detox treatment period. Participants with AUD will be single-blinded randomized into 2 groups - a treatment group (active tAN) and a placebo group (sham tAN). Each group will consist of five separate time points - admission, screening, baseline, tAN treatment, and post tAN treatment. Clinical measures collected before, during, and after treatment will include alcohol withdrawal severity, craving, benzodiazepine usage, and assessments of depression and suicidal behaviors. Participants will undergo MRI scans before and after the treatment period to assess changes in brain connectivity and their relationship to clinical outcomes.
Interventions
- DEVICE Sparrow Ascent
- DEVICE Sparrow Ascent (Sham)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-01-28 |
| Est. Completion | 2026-08-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07281261
The ClinicalTrials.gov registry entry for NCT07281261 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spark Biomedical, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sparrow Ascent is the first listed.
NCT07281261 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07281261 about?
NCT07281261 is a clinical study titled "tAN for Substance Use Disorder". The study will involve a 5-day tAN treatment to attenuate alcohol withdrawal syndrome (AWS) and alter resting state functional connectivity (RSFC) between OFC and striatum in patients with alcohol use disorder (AUD). Enrolled participants will wear the tAN device on-site (at The Menninger Clinic) fo...
What is the current status of trial NCT07281261?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2026-01-28. Estimated completion is 2026-08-31.
What interventions are being tested in trial NCT07281261?
The interventions under investigation include: Sparrow Ascent (DEVICE), Sparrow Ascent (Sham) (DEVICE).
Who is sponsoring clinical trial NCT07281261?
This trial is sponsored by Spark Biomedical, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.